Side-by-side · Research reference
HGH Fragment 176-191vsKisspeptin-10
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongHUMAN-REVIEWED28/59 cited
BPhase 2HUMAN-REVIEWED10/41 cited
HGH Fragment 176-191
GH Fragment · Pre-Clinical
SQ · IP (animal) · Oral (tested)
Kisspeptin-10
Neuropeptide · GPR54 Agonist
Phase 1/2Clinical stage
IV / SQ · Investigational
01Mechanism of Action
Parameter
HGH Fragment 176-191
Kisspeptin-10
Primary target
Beta-3 adrenergic receptors on adipocytesHeffernan 2001
GPR54/Kiss1R on hypothalamic GnRH neuronsRønnekleiv 2026Collado-Sole 2026
Pathway
Fragment → β3-AR upregulation → Enhanced lipolytic sensitivityHeffernan 2001
Kisspeptin → GPR54 activation → GnRH neuronal depolarization → Pulsatile GnRH release → Pituitary LH/FSH secretionLages 2026Rønnekleiv 2026
Downstream effect
Increased lipolysis and beta-3 AR mRNA expression without IGF-1 axis activation
Pulsatile LH surge, FSH elevation, gonadal steroidogenesis, gametogenesis initiationLages 2026
Feedback intact?
N/A — does not interact with GH/IGF-1 axis
Yes — integrates estradiol, leptin, and IGF-1 signals to modulate HPG axisSilva 2026Rønnekleiv 2026
Origin
Synthetic peptide derived from hGH residues 176-191; AOD9604 includes N-terminal tyrosine (177-191)Cox 2015
C-terminal decapeptide of KISS1 gene product; retains full biological activity of longer kisspeptin isoforms
Antibody development
Not reported in available studies
—
02Dosage Protocols
Parameter
HGH Fragment 176-191
Kisspeptin-10
Animal dose (IP)
Not specified (14-day chronic administration)Heffernan 2001
Obese mice, daily IP injection.
—
Human equivalent dose
Not established — no published human RCTs
—
Frequency
Once daily (animal models)
—
Evidence basis
Animal studies only
Phase 1/2 trials
Detection window
50 pg/mL LOD in urine; stable metabolite extends detectionCox 2015
WADA-banned; anti-doping testing available.
—
Oral bioavailability
Demonstrated efficacy in animal oral administrationNg 2000
Potential for oral therapeutic development.
—
Clinical trial dose
—
Phase 1/2 investigational
Dosing protocols vary by indication (hypothalamic amenorrhea, IVF trigger).
Route
—
IV or SQ administration
IV preferred in controlled trials for precise pulsatile delivery.
Half-life
—
Short (minutes)
Rapid clearance; pulsatile dosing mimics physiological GnRH pulse frequency.
03Metabolic / Fat Loss Evidence
Parameter
HGH Fragment 176-191
Kisspeptin-10
Weight gain reduction
50% reduction vs control (15.8 ± 0.6 g vs 35.6 ± 0.8 g)Ng 2000
Obese Zucker rats, 19 days oral administration.
—
Body fat reduction
Significant decrease in body weight and body fat in obese mice (14 days)Heffernan 2001
—
Lipolytic activity
Increased adipose tissue lipolytic activityNg 2000
Direct measurement in treated animals.
—
Insulin sensitivity
No adverse effect — euglycemic clamp confirmedNg 2000
Contrasts with intact hGH diabetogenic effects.
—
IGF-1 impact
No elevation — fragment does not activate GH/IGF-1 axis
—
Beta-3 AR dependency
Effect abolished in β3-AR knockout miceHeffernan 2001
Confirms β3-AR as primary mechanism.
—
Human evidence
None published — pre-clinical only
—
04Side Effects & Safety
Parameter
HGH Fragment 176-191
Kisspeptin-10
Human safety data
Not available — no published human trials
—
Metabolic profile
Six metabolites identified; CRSVEGSCG most stableCox 2015
Detection window implications for doping control.
—
Ovarian hyperstimulation
—
Theoretical risk with supraphysiological dosing in fertility protocols
Headache
—
Mild, reported in early-phase trials
Nausea
—
Transient GI symptoms with IV bolus
Hot flashes
—
Vasomotor symptoms from LH surge
Injection site reaction
—
Erythema, mild discomfort (SQ route)
Absolute Contraindications
HGH Fragment 176-191
- ·Competitive athletes (WADA-banned)Cox 2015
Kisspeptin-10
- ·Active pregnancy
- ·Hormone-sensitive malignancy (breast, ovarian, endometrial)
Relative Contraindications
HGH Fragment 176-191
- ·Absence of human safety data — experimental use only
Kisspeptin-10
- ·Polycystic ovary syndrome (PCOS) without monitoring
- ·Uncontrolled thyroid dysfunction
05Administration Protocol
Parameter
HGH Fragment 176-191
Kisspeptin-10
1. Route
Subcutaneous injection primary route in research context. Oral administration demonstrated efficacy in animal models at 500 mcg/kg.
Reconstitute with sterile water or saline per protocol. Gently swirl — do not shake. Solution should be clear and colorless.
2. Frequency
Once daily dosing used in animal studies. Timing not specified; GH-independent mechanism suggests flexibility.
IV infusion for pulsatile delivery in clinical trials; SQ for outpatient protocols. IV allows precise temporal control of GnRH pulse frequency.
3. Duration
Animal protocols: 14–19 days. Human duration not established — no published trials.
Pulsatile dosing (e.g., every 60–90 min) mimics physiological GnRH pulse generator. Single-bolus protocols used for LH surge induction in fertility research.
4. Storage
Lyophilized peptide storage per standard peptide protocols. Metabolite stability suggests refrigerated reconstituted solution viable.
Serial LH, FSH, estradiol measurements to confirm HPG axis activation. Ultrasound monitoring for ovarian response in fertility applications.
5. Detection
Detectable in urine via SPE-LC-MS at 50 pg/mL LOD. Extended detection window via stable metabolite CRSVEGSCG.Cox 2015
Lyophilized: store at 2–8 °C, light-protected. Reconstituted: refrigerate, use within 24–48 hours per protocol.